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Abstract 29 
Nitric oxide (NO) can be generated endogenously via NO synthases or via the diet following 30 
the action of symbiotic nitrate-reducing bacteria in the oral cavity. Given the important role 31 
of NO in smooth muscle control there is an intriguing suggestion that cardiovascular 32 
homeostasis may be intertwined with the presence of these bacteria. Here, we measured the 33 
abundance of nitrate-reducing bacteria in the oral cavity of 25 healthy humans using 16S 34 
rRNA sequencing and observed, for 3.5 hours, the physiological responses to dietary nitrate 35 
ingestion via measurement of blood pressure, and salivary and plasma NO metabolites. We 36 
identified 7 species of bacteria previously known to contribute to nitrate-reduction, the most 37 
prevalent of which were Prevotella melaninogenica and Veillonella dispar. Following dietary 38 
nitrate supplementation, blood pressure was reduced and salivary and plasma nitrate and 39 
nitrite increased substantially. We found that the abundance of nitrate-reducing bacteria was 40 
associated with the generation of salivary nitrite but not with any other measured variable. To 41 
examine the impact of bacterial abundance on pharmacokinetics we also categorised our 42 
participants into two groups; those with a higher abundance of nitrate reducing bacteria 43 
(>50%), and those with a lower abundance (<50%). Salivary nitrite production was lower in 44 
participants with lower abundance of bacteria and these individuals also exhibited slower 45 
salivary nitrite pharmacokinetics. We therefore show that the rate of nitrate to nitrite 46 
reduction in the oral cavity is associated with the abundance of nitrate-reducing bacteria. 47 
Nevertheless, higher abundance of these bacteria did not result in an exaggerated plasma 48 
nitrite response, the best known marker of NO bioavailability. These data from healthy young 49 
adults suggest that when the host has a functional minimum threshold of these 50 
microorganisms oral nitrate-reducing bacteria will contribute to generation of NO through the 51 
diet, at least.   52 
 53 
 
 
Introduction 54 
NO is a multifunctional signalling molecule which is involved in various biological processes 55 
such as; host defence [1], regulation of mucosal blood flow and mucus generation [2], 56 
regulation of smooth muscle contraction [3], cerebral blood flow [4], glucose homeostasis [5], 57 
and mitochondrial function [6]. Ingestion of inorganic NO3
-
 from sources such as green leafy 58 
vegetables and roots has been consistently shown to increase plasma and salivary [NO3
-
] [7] 59 
and augment NO bioavailability [8]. In this pathway, NO3
-
 is rapidly absorbed in the upper 60 
gastrointestinal tract and enters the circulation [9] before it is subsequently concentrated in 61 
the saliva [10], [11] and a proportion reduced to NO2
-
. Salivary NO2
-
 can be further reduced to 62 
nitric oxide (NO) in certain physiological conditions such as hypoxia or stored in the blood 63 
and tissues for use when endogenous production of NO via NO synthases (NOS) is limited 64 
[12]. As a consequence, ingestion of inorganic NO3
-
 may elicit a myriad of positive biological 65 
effects likely mediated by an increased NO bioavailability. Some studies have demonstrated 66 
that ingestion of NO3
-
−rich beetroot juice can reduce blood pressure (BP) [13], enhance 67 
endothelial function [14], protect against ischaemic injury [15], and improve exercise 68 
performance [16] although these effects are not consistently observed [17], [18], [19].  69 
 70 
The reduction of NO3
- 
to NO2
-
 in saliva is achieved through the action of certain microbes 71 
which reside in the oral cavity [20], [21]. The whole human microbiome is characterised by 72 
body site-specific microbial ecosystems capable of exerting effects on their host through 73 
production of metabolites, immune responses, and gene expression [22].  Some microbes live 74 
in symbiosis with their host and can significantly contribute to health [23], [24]. Conversely, 75 
low diversity of microbial species resulting in dysbiotic states, have been linked to a number 76 
of adverse health conditions including; metabolic syndrome, allergies, asthma, obesity, and 77 
cardiovascular disease amongst others [25].  The oral cavity is heavily colonised by microbes 78 
 
 
and is one site where a symbiotic relationship between humans and bacteria is clearly 79 
evident.  80 
 81 
A series of studies have confirmed the importance of commensal bacteria to the mammalian 82 
enterosalivary cycle, and NO bioavailability. These studies show consistently that rinsing the 83 
oral cavity with chlorhexidine anti-bacterial mouthwash disrupts bacterial enzymatic activity 84 
and abolishes the BP lowering effects associated with dietary NO3
- 
ingestion [26]–[28]. Hyde 85 
and colleagues [21] recently analysed oral microflora from a small sample of healthy human 86 
participants (n = 6) and identified 14 bacterial candidate species that are thought to contribute 87 
to NO3
-
 reduction. The majority of operational taxonomic units (OTUs) with NO3
- 
reducing 88 
capability originated from the genera Granulicatella, Actinomyces, Veillonella, Prevotella, 89 
Neisseria, and Haemophilus. Other studies  have also associated OTUs from the genera 90 
Rothia and Staphylococcus with NO3
- 
reduction [20], [29]. Despite emerging evidence linking 91 
NO3
- 
reducing bacteria with cardiovascular homeostasis no study has explored the 92 
relationship between the abundance of NO3
- 
reducing bacteria in the oral cavity and the 93 
capacity to process dietary NO3
- 
in vivo. This is important because the conversion of NO3
- 
94 
from the diet to NO2
-
 is known to be profoundly variable [30] and the abundance of NO3
- 95 
reducing bacteria may be a rate-limiting step in this process.  96 
 97 
Therefore, our primary objective was to perform descriptive analysis of the abundance and 98 
diversity of oral NO3
-
 reducing bacteria in a larger cohort than previously utilised [21]. The 99 
secondary objective was to determine the association between the abundance of known NO3
- 100 
reducing bacteria with cardiovascular variables and NO biomarkers in blood and saliva. A 101 
further objective was to determine whether participants with a higher abundance of NO3
- 102 
reducing bacteria had different salivary and plasma NO pharmacokinetics following ingestion 103 
 
 
of dietary NO3
- 
compared to those with a lower abundance. 104 
 105 
Methods  106 
Participants 107 
Twenty five healthy adults (age 27 ± 7 years, stature 172 ± 9 cm, body mass 75 ± 15 kg, 11 108 
female) volunteered and provided written informed consent prior to participating in the study. 109 
Ethical approval was provided by the School of Science Ethics Committee at The University 110 
of the West of Scotland.  All participants were in good cardiovascular and oral health, did not 111 
report any habitual use of antibacterial mouthwash, were free from non-prescription 112 
medicines known to interfere with stomach acid production, and were not taking any 113 
prescribed medication. Cardiovascular health status was confirmed by completion of a 114 
medical questionnaire and The World Health Organisation’s oral health questionnaire was 115 
used to ascertain oral health status.  All procedures were conducted in accordance with the 116 
Declaration of Helsinki 1974 and its later amendments.  117 
 118 
Experimental Design  119 
Each participant attended the laboratory on one occasion for this cross-sectional study.  Prior 120 
to the trial, participants were briefed on procedures and provided with an adapted version of 121 
the National Institutes of Health daily food list. The questionnaire was adapted to 122 
differentiate between high, medium, and low NO3
-
 containing foods [31]. Participants were 123 
asked to record their diet for seven days prior to arrival at the laboratory and instructed to 124 
maintain a normal dietary routine. Participants arrived at the laboratory on the morning of the 125 
trial in a fasted and euhydrated state after consuming 500 ml of water. Prior to the trial, 126 
 
 
participants were instructed to avoid strenuous exercise for 24 h and caffeine for 12 h. On the 127 
morning of the trial participants were requested not to brush their teeth or tongue and not to 128 
use mouthwash or chew gum. Participants provided verbal assurance of their compliance 129 
with these instructions.  130 
 131 
Procedures 132 
On arrival at the laboratory, stature and body mass were recorded. Participants then lay 133 
supine for the remainder of the experiment. During the first 30 min a cannula was inserted 134 
into one of the forearm veins and a tongue scrape sample collected. No other physiological 135 
measurements were collected for 30 min to ensure plasma [NO2
-
] had stabilised following the 136 
change in body posture [32]. Following this initial phase, baseline measurements of BP and 137 
heart rate (HR) were recorded and samples
 
of blood and saliva were collected. Participants 138 
then ingested 2 x 70 ml of NO3
-
-rich beetroot juice (~12.4 mmol NO3
-
) (Pro-Elite Shot, James 139 
White Drinks Ltd., Suffolk, England) and physiological measurements were collected at 140 
regular intervals for the next 3.5 h (Fig. 1).  141 
 
 
 142 
Figure 1: Schematic diagram depicting time-course of data collection from 0 h to 3.5 h following the 143 
consumption of NO3
-
-rich beetroot juice 144 
  145 
Blood Collection  146 
Venous blood was collected in 4 ml aliquots in tubes containing ethylenediaminetetraacetic 147 
acid (BD vacutainer K2E 7.2mg, Plymouth, U.K.). Plasma NO2
-
 has been shown to peak, on 148 
average, at 2.5 h after ingestion of beetroot juice [33] so multiple blood samples were taken 149 
before and after this point. Samples of whole blood were immediately centrifuged for 10 min 150 
at 4000 rpm at 4°C (Harrier 18/80, Henderson Biomedical. UK) immediately following 151 
collection.  The plasma was then separated into two cryovials and immediately stored at -152 
80⁰C for later analysis of NO3
- 
and NO2
-
 content via ozone-based chemiluminescence. The 153 
cannula was flushed with 2 ml sterile 0.9% saline immediately following blood draws to keep 154 
the line patent. 155 
 
 
Saliva Collection 156 
Samples of unstimulated saliva were collected via an oral swab (Saliva Bio Oral Swab (SOS) 157 
Salimetrics, Pennsylvania, USA) placed under the tongue for 3 min. Samples of saliva were 158 
collected from 0.5 h onwards as previous data has shown salivary [NO2
-
] and [NO3
-
] may 159 
peak earlier than 1 h [28]. Swabs were then transferred to a collection tube (Sartedt, 160 
Aktiengesellschaft & Co, Numbrecht, Germany) and centrifuged at 4000 rpm for 10 min at 161 
4°C (Harrier 18/80, Henderson Biomedical. UK). Samples were then separated into two 162 
cryovials and immediately stored at -80⁰C for later analysis of NO3
- 
and NO2
-
. 163 
 164 
Measurement of Salivary and Plasma [NO3
-
] and [NO2
-
] 165 
For the analysis of plasma NO2
-
, tri-iodide reagent comprised of 2.5 ml glacial acetic acid, 166 
0.5 ml of 18 Ω deionised water, and 25 mg sodium iodide, was placed in a glass purge vessel 167 
heated to 50°C and connected to the NO analyser (Sievers NOA 280i, Analytix, UK). A 168 
standard curve was created by injecting 100 μL of NO2
-
 solutions at concentrations up to 169 
1000 nM. Plasma and saliva samples were thawed in a water bath at 37°C and 100µL of the 170 
thawed sample was injected immediately into the purge vessel, in duplicate. Saliva samples 171 
were diluted with deionised water at a ratio of 1:100 before injection. NO2
-
 content was 172 
calculated via the area under the curve using Origin software (version 7.1). 173 
 174 
For the analysis of NO3
-
,
 
vanadium reagent consisting of 24 mg of vanadium tri-chloride and 175 
3 ml of 1 M hydrochloric acid was placed into the purge vessel and was heated to 90°C.
 
A 176 
standard curve was created by injecting 25-50 μL NO3
-
 solutions at concentrations up to 100 177 
µM. Plasma samples were de-proteinised using 1 M zinc sulfate (ZnSO4) at 1:10 w/v and 1 M 178 
 
 
sodium hydroxide (NaOH) at a 1:1 ratio. 200 µL of plasma was added to 400 µL of ZnSO4 179 
and 400 µL of NaOH. Each sample was vortexed for 30 s prior to being centrifuged for 5 min 180 
at 4000 rpm. Supernatant was then injected into the purge vessel and concentration calculated 181 
as described for NO2
-
.  182 
 183 
Heart Rate and Blood Pressure  184 
HR was continually monitored via telemetry (Polar Electro, Oy, Finland). Measurements of 185 
BP were recorded in triplicate by standard auscultation using an automated device (Orman 186 
M6, Intelli-Sense. Hoofdorp, the Netherlands).  Mean arterial pressure (MAP) was calculated 187 
using the following equation; 188 
MAP = (2 x diastolic BP + systolic BP) / 3 189 
 190 
Tongue Scrape and Bacteria Collection 191 
Bacteria were collected from the posterior dorsal surface of the tongue using a sterile metal 192 
tongue cleaner (Soul Genie, Health Pathways LLP, Uttar Pradesh, India). This area of the 193 
mouth has previously been shown to contain a high abundance of NO3
-
 reducing bacteria as 194 
they favour the anaerobic environment provided by the deep crypts of the tongue [20]. The 195 
tongue cleaner was gently glided from the back to the front of the tongue until there was a 196 
visible coating on the instrument [21]. Tongue scrape samples were subsequently transferred 197 
via a sterile sample collection swab (Deltalab, S.L. Barcelona, Spain) to a MoBio Powersoil 198 
DNA Isolation Kit (MoBio Laboratories Inc. West Carlsbad, California) and immediately 199 
frozen at -80⁰C. Bacterial DNA was subsequently extracted using the MoBio Powersoil 200 
Isolation Kit according to the manufacturer’s guidelines. 201 
 
 
Bacterial Analysis 202 
DNA was transported to a commercial centre (HOMMINGS, The Forsyth Institute, Boston 203 
MA, USA) for sequencing analysis. A full description of the protocol is described in previous 204 
research [34]. In brief, the V3-V4 region of the bacterial genomic DNA was amplified using 205 
barcoded primers; ~341F (forward primer) 206 
(AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTCCTACGGGAGGCA207 
GCAG) and ~806R (reverse primer) 208 
CAAGCAGAAGACGGCATACGAGATNNNNNNNNNNNNAGTCAGTCAGCCGGACT209 
ACHVGGGTWTCTAAT). 210 
Samples (10 – 50 ng) of DNA were PCR-amplified using V3-V4 primers and 5 211 
PrimeHotMaster Mix and purified using AMPure beads. A small volume (100 ng) of each 212 
library was pooled, gel-purified, and quantified using a bioanalyser and qPCR. Finally, 12pM 213 
of the library mixture, spiked with 20% Phix, was analysed on the Illumina MiSeq (Illumina, 214 
San Diego, CA).  215 
 216 
16s rRNA gene data analysis 217 
Quality filtered data received from the sequencing centre was further analysed for taxonomic 218 
classification and bacterial abundance using Qiime 1.8 [35]. One sample with less than 5000 219 
reads was discarded from further analysis. Sequences were clustered de novo and binned into 220 
OTUs based on 97% identity.  Taxonomy was assigned using RDP classifier trained to the 221 
GreenGenes database (October 2013 release). Singleton reads were removed from the 222 
dataset. In order to calculate alpha diversity metrics, the OTU table was sub-sampled to 223 
20090 reads per sample and repeated 5 times. The mean values were then calculated across 224 
the 5 sub-sampled OTU tables and used to calculate alpha diversity metrics. The smallest 225 
 
 
number of reads associated with any one sample was 20094 reads.  To analyse the effect of 226 
bacterial abundance on pharmacokinetic changes in response to NO3
-
, participants were split 227 
into two groups; those with a higher overall abundance (>50%) of NO3
-
 reducing bacteria 228 
(High) and those with a lower abundance (<50%) (Low).  229 
 230 
Statistical Analysis 231 
Statistical Package for the Social Sciences (SPSS Version 22.0. Armonk, NY: IBM Corp) 232 
was used for statistical analysis. GraphPad Prism version 7 (GraphPad Software Inc., San 233 
Diego, USA) was used to create the figures. The distributions of data were assessed using the 234 
Shapiro Wilk test and non-parametric tests were used where data were not normally 235 
distributed. A one-way repeated measures ANOVA was used to assess changes in plasma and 236 
salivary NO3
- 
and NO2
-
, and BP measurements.  237 
 238 
The association between the abundance of NO3
- 
reducing bacteria and peak values of plasma 239 
and salivary NO variables was analysed using the Spearman’s rank correlation co-efficient. 240 
Peak delta values were defined as the value with the biggest change from baseline. The 241 
association between the abundance of NO3
- 
reducing bacteria and the area under the curve for 242 
salivary nitrite across the experiment was calculated using the same method.  243 
 244 
Differences in bacterial abundances between Low and High groups were assessed using an 245 
independent t test. A two-factor mixed model ANOVA (group and time) was used to 246 
compare differences in BP and NO metabolites between groups and gender.  Data are 247 
presented as mean ± standard deviation unless otherwise stated. Statistical significance was 248 
 
 
declared when P ≤ 0.05. Probability values are expressed with 95% confidence intervals 249 
(95% CI) where appropriate. 250 
 251 
Results  252 
Ingestion of dietary NO3
- 
raises plasma and salivary NO metabolites and lowers blood 253 
pressure 254 
Salivary and plasma NO2
-
 and NO3
-
 were increased at all time points compared to baseline 255 
(all P < 0.001), with the exception of plasma NO2
-
 at 1 h (P = 0.1). Ingestion of beetroot juice 256 
significantly reduced SBP (P = 0.018, 95% CI 1 - 6 mmHg) and DBP (P = 0.045, 95% CI 1 - 257 
4 mmHg) at 2.5 h. MAP was significantly lower at 1.5 h (P = 0.01, 95% CI 1 - 5 mmHg), 2 h 258 
(P = 0.03, 95% CI 1 - 4 mmHg), and 2.5 h (P = 0.05, 95% CI 1 - 4 mmHg) (Figure 2). Mean 259 
HR tended to be lower overall after NO3
-
 ingestion (P = 0.07) but there was no significant 260 
main effect for HR at any specific time point (all P > 0.05). There were no significant 261 
differences between males and females for any variable (all P > 0.05). 262 
 
 
 263 
Figure 2. Graphs show change in NO metabolites from baseline after ingestion of beetroot juice. Salivary nitrite 264 
(A), plasma nitrite (B), salivary nitrate (C) and plasma nitrate (D). * denotes significant increase from baseline 265 
(P<0.05).   266 
 
 
 267 
Figure 3. Graphs show change in BP from baseline to 3.5 h after ingestion of beetroot juice. SBP (A), DBP (B) 268 
and MAP (C). Value shown are mean ± SD, * denotes significant decrease from baseline, (P < 0.05).   269 
 270 
Comparison of nitrate reducing communities of healthy human tongues 271 
After quality filtering of the data and removal of singleton reads, tongue scrapings of 24 272 
subjects were included in the analysis. Alpha diversity metrics revealed that samples were 273 
diverse with an average of 1165 ± 157 OTUs. The Shannon diversity index was 5.2 ± 0.6, 274 
however, there was notable variation in relative abundance. Previous in vitro work [21]  275 
suggests that the genera displayed in Table 1 contribute to NO3
- 
 reduction. Some of these 276 
 
 
were amongst the top five most abundant genera as indicated by the blue shaded area (Table 277 
1).  278 
 279 
Table 1, % relative abundance of genera present in our samples which 280 
have previously been implicated in nitrate reduction. The blue shaded 281 
area indicates the top five most abundant genera identified overall.  282 
OTU ID 
Mean ± 
SD (%)   Max (%)  Min (%) 
Prevotella 42.12 ± 10.09 63.43 19.92 
Veillonella 20.55 ± 12.31 45.5 6.07 
Leptotrichia 4.13 ± 4.11 13.91 0.02 
Fusobacterium 3.60 ± 3.89 13.56 0.01 
Haemophilus 2.84 ± 1.63 6.06 0.00 
Neisseria 2.60 ± 5.50 20.54 0.00 
Actinomyces 0.84 ± 3.77 14.52 0.05 
Porphyromonas 0.47 ± 0.81 2.6 0.00 
Rothia 0.41 ± 0.53 20.54 0.00 
Granulicatella 0.14 ± 0.14 0.014 0.00 
 283 
We found seven of fourteen known species which have previously been identified as having a 284 
NO3
-
 reduction gene (Table 2). It has been suggested that bacteria do not work independently 285 
but as consortium. To reflect this, we calculated the total % relative abundances of the seven 286 
NO3
-
 reducing bacteria shown in Table 2. We assessed if gender influenced the abundance of 287 
nitrate reducing bacteria finding that there were no significant differences (P > 0.05).   288 
 289 
 290 
 291 
 292 
 293 
 294 
 295 
 296 
 297 
 298 
 
 
Table 2, % relative abundance of NO3
-
 reducing species  299 
  Species Mean ± (%) 
Prevotella melaninogenica 31.43 ± 10.33 
Veillonella dispar 19.30 ± 11.97 
Haemophilus parainfluenzae 2.78 ± 3.83  
Neisseria subflava 2.57 ± 5.52 
Veillonella parvula 0.24 ± 0.46 
Rothia mucilaginosa 0.37 ± 0.49 
Rothia dentocariosa 0.003 ± 0.004  
 300 
High abundance of nitrate reducing bacteria correlates with high salivary nitrite 301 
response 302 
The correlation analysis between the sum of the NO3
-
 reducing species (identified in Table 2) 303 
and the peak delta change in relevant physiological measurements are displayed in Figure 4. 304 
The abundance of NO3
-
 reducing bacteria was significantly correlated with the change in 305 
salivary NO2
-
 (P = 0.03, r = 0.44, Fig. 3A) but not with any other variable (all P > 0.05). The 306 
area under the curve for salivary NO2
-
 (3010 ± 614.52 µM) was also significantly correlated 307 
with the sum of the NO3
-
 reducing species (P = 0.05, r = 0.40). 308 
 
 
   309 
Figure 4. Correlations between the sum of NO3
-
 reducing bacteria and peak change in salivary NO2
-
 (A) plasma 310 
NO2
-
 (B), salivary NO3
-
 (C), plasma NO3
- 
(D). * denotes significance, (P<0.05).   311 
 312 
Impact of bacterial abundance on pharmacokinetics and pharmacodynamics following 313 
acute NO3
-
 ingestion 314 
Seven participants were identified as having less than 50% total relative abundance of the 315 
NO3
-
  reducing species identified in their tongue scrapes and were classified to the Low 316 
group. The remaining participants were classified as the High group. At the OTU level, 317 
40.99% ± 6.11% NO3
-
  reducing species were observed in the Low group compared with 318 
62.64% ± 6.92% in the High group (Figure 5).  319 
 
 
 320 
 321 
Figure 5. A comparison of the relative abundance of NO3
-
 reducing species between those classified as having a 322 
high (>50%) or low (<50%) overall abundance of NO3
-
 reducing bacteria. Data are presented as group means 323 
with S.D. excluded for clarity. Rothia dentocariosa is not shown due to low abundance (high group 0.003 ± 324 
0.001 %, low group 0.002 ± 0.001 %).  325 
 326 
At both species and genera level, the sum of NO3
-
 reducing bacteria was significantly higher 327 
in the High group compared to the Low (species level: P < 0.05, 95% CI 15 – 28%; genus 328 
level P < 0.05, 95% CI 11 – 21%). Alpha diversity metrics revealed that bacterial species in 329 
the tongue scrape samples of the Low group were more diverse than the high group (P < 330 
0.001, 1279 ± 136 vs. 1098 ± 129 OTUs, respectively). The Shannon diversity index was also 331 
higher in the Low group compared to the High group (P = 0.002, 5.9 ± 0.0 vs. 4.9 ± 0.6, 332 
respectively). There were no differences in the consumption of high, medium, and low NO3
- 
333 
vegetables or cured meats between groups. Nor was there any difference in baseline values 334 
for any physiological variable (all P > 0.05, Table 3). 335 
 336 
 337 
 
 
Table 3, baseline values for the high and low groups. Values are mean ± 338 
standard error of the mean 339 
 High Group 
Mean ± SEM 
Low Group 
Mean ± SEM 
SBP (mmHg) 120 ± 3 123 ± 4 
DBP (mmHg) 68 ± 16 71 ± 27 
MAP (mmHg) 85 ± 2 88 ± 3 
Salivary Nitrite (µM) 227 ± 43 168 ± 97 
Salivary Nitrate (µM) 933 ± 226 549 ± 207 
Plasma Nitrite (nM) 131 ± 32 151 ± 61 
Plasma Nitrate (µM) 39 ± 10 27 ± 11 
 340 
Salivary NO2
-
 peaked earlier in the High group (1.6 ± 1 h) compared to the Low (3 ± 0.6 h, P 341 
= 0.04). Salivary NO2
-
 was significantly higher in the High group compared to Low at 1.5 h 342 
(P = 0.02, 95% CI 130 – 1320 µM) and 2 h (P = 0.01, 95% CI 182 – 1375 µM) after 343 
ingestion of beetroot juice. There were no other differences between groups for salivary NO3
-
 344 
or plasma NO metabolites (all P > 0.05) (Figure 6). The time to peak for salivary NO3
-
, 345 
plasma NO metabolites, and BP measurements were also not different between groups (all P 346 
> 0.05).  347 
  348 
 
 
 349 
350 
Figure 6. Change relative to baseline in salivary NO2
-
 (A), plasma NO2
-
 (B), salivary NO3
-
 (C), plasma NO3
-
 (D). 351 
Data are displayed as means and standard error of the mean. * denotes significant differences between groups, 352 
(P < 0.05).  353 
 354 
Discussion 355 
Despite the emergent importance of the enterosalivary NO3
-
, NO2
- 
to NO pathway for 356 
cardiovascular health, no study has directly investigated the association between the 357 
abundance of NO3
-
 reducing bacteria in the oral cavity and the capacity to reduce exogenous 358 
NO3
-
 to NO2
- 
 in vivo. Guided by previous work [20], [21], [36], we first investigated the 359 
abundance of known NO3
-
 reducing bacteria through 16s rRNA gene sequencing. We provide 360 
descriptive data at both genus and species level in a much larger sample size than has been 361 
 
 
reported previously in healthy humans. In addition, this is the first description of sequencing 362 
data in conjunction with in vivo measurements to demonstrate that the abundance of NO3
-
 363 
reducing bacteria on the dorsal surface of the tongue significantly correlates with salivary 364 
NO2
- 
generation following the ingestion of NO3
- 
rich beetroot juice. A higher abundance of 365 
these bacteria also results in a more rapid reduction of salivary NO3
-
 to NO2
-
. Despite this, 366 
higher abundance of oral NO3
-
 reducing bacteria does not appear to exaggerate changes in 367 
plasma NO2
-
 or BP following ingestion of beetroot juice, at least in this young healthy cohort. 368 
 369 
16S rRNA gene sequencing analysis of the healthy human tongue microbiome 370 
Our samples were similar in bacterial diversity to those reported previously [21], [37]. At the 371 
genus level, all genera previously implicated in NO3
-
 reduction [20], [21] were detected. 372 
Prevotella and Veillonella were found to be the first and second most abundant genera in our 373 
samples, respectively. In contrast, previous research has typically identified Veillonella as the 374 
most abundant taxa found on the tongue dorsum [21]. Although direct comparison cannot be 375 
made between studies due to differences in sequencing platforms and culturing methods, 376 
these findings support the notion that the composition of the microbiome may differ 377 
profoundly, even in healthy individuals [38]. 378 
 379 
Through 16s RNA sequencing we identified only seven of fourteen known species which 380 
have previously been demonstrated to reduce NO3
-
 in vitro (Table 2) [21]. In this previous 381 
work, three tongue scrape samples were analysed using whole genome shotgun sequencing 382 
(WGS) to identify bacterial species followed by metabolic pathway reconstruction to 383 
determine NO3
-
 reduction capacity. Given that WGS sequences all genes rather than the more 384 
 
 
targeted approach of 16s RNA sequencing, this method allows for a more accurate taxonomic 385 
assignment at species level and likely explains the disparity in the experimental outcomes. 386 
Nevertheless, we analysed a far greater number of samples (n=24) than has been reported in 387 
previous research [21] which seems necessary given the aforementioned variability in the 388 
abundance of bacterial species within the oral microbiome.  389 
 390 
Impact of bacterial abundance on the reduction of salivary NO3
- 
to
 
NO2
-
 391 
Next, we examined how the abundance of NO3
-
 reducing bacteria influenced 392 
pharmacokinetics and pharmacodynamics following ingestion of a standardised dietary NO3
-
 393 
dose. In line with previous research [26], [27], [39] , the ingestion of NO3
-
 rich beetroot juice 394 
resulted in a marked elevation of NO metabolites in the plasma and saliva. A novel finding of 395 
this study is that the abundance of known oral NO3
-
 reducing bacteria was associated with the 396 
peak increase in salivary NO2
- 
concentration
 
following ingestion of dietary NO3
-
. 397 
Furthermore, NO2
- 
peaks earlier in the saliva following ingestion of beetroot juice in 398 
individuals who have a higher abundance of these bacteria. These data are perhaps 399 
unsurprising given that oral bacteria are known to play a crucial role in the reduction of 400 
salivary NO3
-
 to NO2
-  
[26]–[28]. Nevertheless, where previous research has established that 401 
the presence of NO3
- 
reducing bacteria is essential, we show that the abundance of these 402 
bacteria seems to impact the magnitude of salivary NO2
- 
accumulation in the presence of 403 
elevated salivary NO3
-
. It is, however, important to acknowledge that these analyses do not 404 
necessarily imply “cause-effect” relationship between bacterial abundance and salivary NO2
- 405 
generation. Other factors, including the efficiency of NO3
-  
transport via sialin in the salivary 406 
glands [9], [40], inhibition of stomach acid production [41], and the metabolic activities of 407 
bacteria [21], may also influence this process. Our findings contrast with previous in vitro 408 
 
 
analysis of three isolated samples which suggested that the NO3
-
 reducing capacity of oral 409 
bacterial species was not influenced by the metabolic pathway coverage or the abundance of 410 
these bacteria [21]. It is evident, therefore, that whilst computational and in vitro methods are 411 
useful in determining characteristics of microbes in a controlled environment, there is a 412 
further challenge in determining the functional capacity of a microbial community, especially 413 
when attempting to relate outcomes to the dynamic in vivo environment.   414 
 415 
Impact of bacterial abundance on plasma pharmacokinetics and BP 416 
Despite the association with salivary NO2
-
,
 
the abundance of NO3
- 
reducing
 
bacteria was not 417 
related to the change in plasma NO2
- 
or BP markers. Nor did a higher abundance of these 418 
bacteria alter plasma pharmacokinetics following the ingestion of beetroot juice. This has 419 
important implications since plasma NO2
-
 is considered to provide the best approximation of 420 
circulating NO bioavailability [42], [43] and is suggested to be a marker of endothelial 421 
function [44] and cardiovascular risk [45]. While some have proposed that salivary NO2
- 
may 422 
be a useful point of care diagnostic for assessing total body NO bioavailability [46], the 423 
discordance between salivary and plasma changes in NO2
-
 observed in the present study 424 
would seem to refute this suggestion for healthy young subjects.
  425 
 426 
Our data suggests that, at least in this homogenous sample, higher abundance of NO3
-
 427 
reducing bacteria does not seem to further increase circulating NO bioavailability. Whilst it is 428 
useful to characterise the healthy human microbiome in this context, it is necessary to further 429 
explore these data in populations with compromised NO bioavailability, including older 430 
adults [47], patients with endothelial dysfunction [48], and those treated with antibiotics [49] . 431 
 
 
Furthermore, it should be acknowledged that while some participants were classified as 432 
having a “low” abundance of NO3
- 
reducing bacteria, this cohort still had 41 ± 6% of taxa 433 
which possess a NO3
-
 reductase gene (with the lowest abundance being 29%) and all 434 
experienced a substantial increase in plasma NO metabolites. Previous work by Woessner 435 
and colleagues [28] demonstrated a stepwise reduction in salivary NO2
-   
and BP responses 436 
when differing strengths of mouthwash were administered which further supports the notion 437 
that the magnitude of NO3
-
 conversion is related to the abundance of NO3
- 
reducing bacteria. 438 
The apparent consequence of the lower abundance of these bacteria is that salivary NO3
-
 439 
reduction occurs at a slower rate than those in the high group but the appearance of salivary 440 
NO2
- 
can continue to accelerate at least up to 3 h after ingestion of a NO3
-
 dose. It would, 441 
therefore, be of interest to collect further data from individuals with an altered microbiome 442 
such as that which might occur with ageing [23][22] or periodontal disease [50]. 443 
 444 
There are a number of reasons why an augmented salivary NO2
-
 concentration was not 445 
paralleled by the expected additional increase in plasma NO2
-
 but these remain speculative 446 
until further experimental data is collected. Firstly, it may be that “excess” NO2
-
 from the 447 
saliva is excreted via the urinary system. NO3
-
 and NO2
-
,
  
originating from either exogenous 448 
and endogenous sources, have been shown to be excreted in the urine [51]. This suggests that 449 
there may be a saturation threshold for circulating NO2
- 
over which the excess is either stored 450 
or excreted. This may be to prevent excessive drops in BP which would be detrimental to 451 
homeostasis [52]. Future studies could include urine collection and analysis to verify this 452 
hypothesis. Alternatively, the lack of accordance between oral bacterial abundance and 453 
plasma NO2
-
 may be due to the generation of NO2
-
 at sites outside the oral cavity. NO3
-
 454 
reduction is thought to occur in the gastrointestinal tract, for example, through conversion to 455 
bioactive nitrogen oxides via hydrogen chloride [1]. Vermerien and colleagues [53] also 456 
 
 
showed that, in conditions simulating the colon, faecal microbiota can reduce NO3
-
 to NO via 457 
dissimilatory reduction to ammonia. Given that NO possesses a very short in vivo half-life it 458 
may then be rapidly oxidised back to NO2
- 
and
 
NO3
- 
[43][42][41][40]. It must also be 459 
acknowledged that there are many storage forms of NO in the red blood cells and plasma that 460 
may exert physiological effects, including s-nitrosothiols [41] and nitrated lipids [54] It is 461 
possible, therefore, that plasma NO2
-
 may simply be a marker of NO availability [41] and not 462 
the intermediate directly responsible to the reduction in BP resulting from NO3
- 
administration. 463 
 464 
Conclusions 465 
We show in vivo in healthy adults that there is a positive linear relationship between the total 466 
relative abundance of commensal NO3
-
 reducing oral bacteria and the generation of salivary 467 
NO2
-
 following a dose of dietary NO3
-
. While these data are cross-sectional and correlative in 468 
nature, these findings are significant given the supposed therapeutic benefits of dietary NO3
-
 469 
supplementation. Nevertheless, a higher relative abundance of NO3
- 
reducing bacteria did not 470 
result in further increases in plasma NO2
-
 concentration (a marker of vascular NO 471 
bioavailability) and nor did it influence the extent by which BP was reduced following 472 
ingestion of NO3
-
-rich
 
beetroot juice. This suggests that where sufficient quantities of these 473 
bacteria are present on the tongue, dietary NO3
-
 supplementation will consistently increase 474 
circulating NO with potentially meaningful biological consequences. Further work should 475 
explore these phenomena in populations with compromised endogenous NO generation 476 
capacity or with an altered oral microbiome to better understand the link between commensal 477 
bacteria and cardiovascular health. 478 
 479 
 480 
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